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Clinical implications of abundant calcium phosphate in rou-
tinely analyzed kidney stones.
Background. To better portray the clinical phenotype of kid-
ney stone patients with high calcium phosphate (CaP) stone
abundance, we present here clinical and laboratory findings of
large numbers of stone formers (SF) with stone CaP ranging
from 0% to 100%. Our purpose was to inform clinicians and
highlight areas that seem to deserve further research.
Methods. We calculated average percent CaP (CaP%) in all
stones of 1201 patients, and classified them into CaOx (N =
1011) or CaP (N = 190). Sex differences, stone formation rates,
urine stone risk factors, extracorporeal shock wave lithotripsy
(ESWL) treatments, and relapse during treatment were quan-
tified in relation to stone CaP content.
Results. CaP% has risen for three decades, especially among
women. ESWL rates adjusted for numbers of stones and dura-
tion of stone disease were higher in CaP SF (0.6 vs. 1.86 and
0.73 vs. 1.82, CaOx vs. CaP, men and women, respectively, P <
0.001), and especially when stones contained brushite (2.90 vs.
1.02 and 3.11 vs. 1.35, brushite vs. not, males and females, re-
spectively, P < 0.001). Urine pH and CaP supersaturation rose
in proportion to CaP% in a dose response manner. Relapse
rates of CaP and CaOx SF did not differ, and both did well with
medical prevention.
Conclusion. Stone CaP% has risen for three decades. CaP
SF, particularly with brushite stones, receive more ESWL treat-
ments than CaOx SF, not explained by stone number or dura-
tion of stone disease. Urine supersaturations explain the high
CaP%. High CaP% does not hamper medical stone prevention.
We explore here the clinical importance of calcium
phosphate (CaP) found in kidney stones by routine stone
analysis. Most routine analyses report kidney stones as
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mixtures, usually predominant calcium oxalate (CaOx)
admixed with small amounts of such CaP phases as ap-
atite and other basic CaP phases, denoted as CaP(b),
and brushite (calcium monohydrogen phosphate), de-
noted as BR. In a minority of patients, CaP is the
main stone phase (CaP stone formers). We used routine
commercial stone analyses, but otherwise, studied our
patients using our own laboratory measurements and
clinical observations. With this amalgam of commercial
and research level results, we have found and reported
high CaP supersaturation (SS) in CaP stone formers, and
high CaOx or uric acid SS in corresponding patients form-
ing those stones [1, 2]. SS is the accepted gauge of the
thermodynamic driving forces for crystal formation and
growth [1, 2]. Routine commercial stone analyses must
therefore be informative, even though they vary in tech-
nique, and perhaps quality, because otherwise urine SS
could not be so predictive of stone phase.
Here we extend our past work to define as well as we
can the clinical phenotype of the CaP stone former. What
are reasonable limits for diagnosing a ‘CaP stone former?’
Is stone CaP content higher among females and gener-
ally increasing with time, as has been reported [3]? Can
we show the proportional increase of urine CaP SS with
increasing stone CaP content that would be expected if
we were correctly measuring both urine driving forces
for CaP formation in stones and stone CaP content? Are
there clinical correlates of the distinction between CaP(b)
and brushite in stones [4]? Do patients with high stone
CaP content, both brushite and CaP(b), form more stones
[5]? Do they undergo more extracorporeal shock wave
lithotripsy (ESWL) than those with CaOx stones, and do
patients with brushite in their stones have the most ESWL
procedures, as has been suggested elsewhere [4]? Is stone
prevention as effective for CaP as for CaOx stone for-
mers? Finally, are there distinctions between CaP stone
formers whose stones contain any BR (brushite stone for-
mers), as opposed to those whose CaP stones are entirely
composed of CaP(b)?
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Fig. 1. Distributions of CaP, CaP(b), and
brushite in stones. Fraction of CaP, calculated
as the average CaP percent in all stones ana-
lyzed from our 1201 patients (A) had a high
peak near 0, and a tiny peak near 100%. A
log(10) transformed version (inset) shows a
peak at 1% CaP, a broad band between 1%
and 15%, and a peak beginning near 70%
and terminating in an intercept (vertical line
height at 100%) at 100% CaP. From these,
eight practical divisions were made for anal-
ysis (see Methods). Among the 190 patients
classified as CaP stone formers (see Methods),
CaP(b) in stones (B, dashed line) peaked at
about 10%, and then exhibited a broad peak
beginning at about 50%, followed by a final
peak between 90% and 100%. Brushite (con-
tinuous line) has only tiny peaks below 70%.
From this, cut points of 50% and 70%, re-
spectively, were chosen to delineate CaP(b)
and brushite stone. Not stated elsewhere, but
an important clarification, the patients with
<50% CaP classified as CaP stone formers
were in the brushite group.
METHODS
Patients and routine measurements
From our patients whose stones had been analyzed, we
excluded those with cystine, uric acid, or struvite stones,
or with stones due to bowel disease, Sjogrens syndrome,
hereditary renal tubular acidosis (RTA), acetazolamide
use, or primary hyperparathyroidism, leaving 1201 for
this report. Their stones ranged from 0% to 100% CaP.
All patients had been evaluated using the protocol de-
scribed from this program [2, 6], which involved three
24-hour urine collections before treatment, each with a
corresponding blood sample drawn between 7 and 9 a.m.,
12 hours after eating. As well, we obtained additional
studies, performed in the same manner during treatment.
Urine measurements included urine volume and pH, and
daily excretions of calcium, phosphate, magnesium, ox-
alate, sodium, potassium, creatinine, uric acid, sulfate,
ammonia, and citrate. Routine urine stone risk factors
were calculated in the usual manner, including SS values
[2]. Serum calcium was used to exclude primary hyper-
parathyroidism. Serum electrolyte measurements were
used to exclude overt renal tubular acidosis. Serum re-
sults are not presented here.
As in our other studies, we used stone analyses from a
variety of commercial laboratories, excluding only those
based on chemical analyses. Two vendors accounted for
over 90% of all analyses; the remaining 10% arose from
outsourcing from large national laboratories. One ven-
dor had only used infrared spectroscopy. The large out-
source laboratories indicated that technology was used, as
well. The other vendor (personal communication) used a
mixture of infrared and x-ray diffraction throughout our
history of use. In other words, all of our analyses were
provided by infrared spectroscopy or x-ray diffraction.
We obtained follow-up blood and urine measurements
during treatment according to protocols published else-
where [7, 8], along with radiographs and personal assess-
ment to determine stone relapse. Here, we present stone
relapse data for CaP and CaOx stone formers from whom
we obtained laboratory measurements during treatment.
We cannot detail treatments, except to note that our pro-
tocol used thiazide diuretics for all hypercalciuria unless
otherwise impossible [6, 7, 8], and is sparing of potassium
citrate salts when urine pH is consistently above six. High
fluid intake and reduced sodium intake were also sought,
with variable results documented elsewhere [9]. For hy-
peruricosuric calcium oxalate stone formers, we used al-
lopurinol [10] when clinically indicated; diet modification
was used otherwise.
The distribution of mean CaP in kidney
stones formed by individual patients
We calculated the average percent of calcium phos-
phate in all stones from each patient as a fraction of total
stone composition (CaP%; Fig. 1, left panel), and derived
eight groupings of CaP% from the distributions. A num-
ber of patients had no phosphate in their stones (Fig. 1,
left panel). From the logged inset figure, 1% CaP was a
distinct group, as was the broad peak between 1% and
20%. We arbitrarily chose the region from >0% to 10%,
and from 10% to 20%, as two groups. We arbitrarily di-
vided the featureless plateau between 20% and 70% into
approximately equal groups: 20% to 50% and 50% to
70%. The regions from 70% to 90% that peaked at about
90%, between 90 and 100%, and 100% completed the
eight groups: 0%, >0%–10%, >10%–20%, >20%–50%,
>50%–70%, >70%–90%, >90%–99.9%, and 100%. For
clarity, the ‘greater than’ signs signifying actual division
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points are omitted from figures and text. These eight di-
visions have arbitrary elements, but are nonetheless rea-
sonable for this study.
Classification of patients by stone type
CaP(b) abundance was rather bimodal, having a peak
of patients with stones below 30% CaP(b), and another
peak that rose steeply above 50% (Fig. 1, right panel).
Very few patients had brushite abundance below 50%,
and most were above 70%. Therefore, we labeled pa-
tients with more than 50% CaP(b) in any stone and no
brushite in any stone CaP(b) stone formers, and those
with brushite in any stone brushite stone formers. The ra-
tionale for brushite was this: the vast majority of patients
whose stones contained any brushite formed stones that
were mainly brushite, so for clinical purposes it is a robust
simplification to consider any brushite as a qualitative
distinction. The majority of patients who had no brushite
and less than 50% CaP(b) in any stone were labeled CaOx
stone formers. We batched CaP(b) and brushite stone for-
mers together as CaP stone formers for convenient nar-
ration. Using these definitions, 1011 patients were CaOx
stone formers, 73 were brushite stone formers, and 117
were CaP(b) stone formers, the latter two giving 190 CaP
stone formers as their sum (Table 1).
Other clinical variables
The numbers of stones and ESWL procedures were
summed before and during treatment for each patient.
Duration of stone disease was calculated in years from
the date of first stone until our last contact with the pa-
tient. Relapse stones, those during treatment not on prior
radiographs [7], were also counted. We did not calculate
rates of stones per patient per year, but used number of
stones and duration of stone disease as covariates in anal-
ysis of variance (ANOVA) or general linear models.
Statistical analyses
The two sexes, the three stone groups (CaOx, brushite,
and CaP(b)), and the eight levels of CaP% were used as
factors in ANOVA, with various urine measurements and
other continuous variables as dependent, or covariates. In
the case of stone CaP% over decades of observation, we
plotted individual stone CaP% against half decade since
1970, and did post-hoc contrasts to determine the signifi-
cance of time-related changes. For clarity, all ANOVA re-
sults were tabulated (Table 2). Adjusted means are given
in the text, along with the analysis number of Table 2 con-
taining the analysis, and when necessary, the specific line
within the analysis entry. Routine t tests were performed
as needed. In some analyses, general linear models were
used to allow step-wise entry of variables in order to as-
sess their relative contribution to regressions, to assess
Table 1. Types of stone formers
Type of patient Male Female Both
CaOX 750 261 1011
CaP 101 89a 190
Brushite 48 25 73
CaP(b) 53 64b 117
Abbreviations are: CaOx, calcium oxalate stones; CaP, >50% calcium
phosphate in any stone or any brushite; Brushite, any brushite in any stone;
CaP(b), >50% CaP in any stone and no brushite in any stone.
aFraction female differs from CaOx, P < 0.0001; b fraction female differs from
brushite, P < 0.006.
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Fig. 2. Sex distributions at increasing fraction of CaP in stones. Num-
bers of men (gray bars) and women (black bars) were highest at low
CaP fraction (x-axis), and percent females (black circles connected by
lines) were low. As CaP% increased, percent female increased, so that
at a CaP% above 90, females predominated.
specific cross products of factors and continuous covari-
ates, and homogeneity of slopes. All computations used
standard software (SYSTAT, Richmond, CA, USA).
RESULTS
Females predominate among CaP SF
and stone CaP% increases over time
Females predominated among the 190 CaP versus the
CaOx stone formers (Table 1); CaP(b) stone formers
were more frequently female, brushite more frequently
male. As a corollary, patient groups with increasing
CaP% were progressively female (Fig. 2, solid dots con-
nected by lines). Between 1970 and today (Fig. 3), stone
CaP% in both sexes have increased about three-fold.
Stones from females (Fig. 3, filled symbols) were higher
in CaP% throughout (Fig. 3 and Table 2; analysis 1).
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Fig. 3. Change in stone CaP over three decades. Mean values for stone
CaP% are plotted against the time period (half decade) of the stone
analysis. For stones from females (closed circles) and males (open cir-
cles) alike, CaP% in stones rose between 1970 and 2003. Females were
higher throughout. The increases for both sexes over time were signifi-
cant using analysis of variance (ANOVA) with post-hoc contrasts (see
Results), as was the higher female CaP%.
The increase in CaP% over time was significant by
ANOVA with post-hoc contrasts (Table 2; analysis 1).
CaP stones begin younger, and men
form more stones than women
CaP stone disease begins at a younger age (29.8 vs.
33.6, CaP vs. CaOx stones), whereas the sex difference
in age of stone onset (30.9 vs. 32.6, females vs. males),
when adjusted for stone type, was not significant (Table
2; analysis 2). Duration of stone disease adjusted for age at
first stone and stone type (Table 2; analysis 3) was higher
in men (16.6 vs. 12.5, male vs. female); stone type itself
was not significant. Follow-up intervals in our program
did not explain sex differences in stone disease duration
(analysis not shown). Men formed more stones (24 vs.
13 stones, male vs. female); stone type (CaOx vs. CaP)
and duration of stone disease were not significant (Table
2; analysis 4). In other words, CaP patients begin their
stones younger, but do not form more stones during a
given interval of disease, nor do they have an interval
of disease different from CaOx stone formers. Men form
more stones than women, even allowing for their longer
stone disease interval.
Urine CaP SS and pH rise with stone CaP%
Pretreatment urine CaP SS and urine pH rose with
stone CaP% (Fig. 4, upper left and middle panels) in
men (open circles) and women, exhibiting joint propor-
tional increases up to a plateau SS value of 2 to 2.5. In
men and women (Fig. 4, upper right panel), urine cal-
cium rose with CaP%, and reached a plateau between
50% and 70% CaP. In women, urine calcium then fell
as CaP% increased further. CaP patients excreted more
calcium (247 vs. 298 and 198 vs. 266 mg/d, CaOx vs. CaP,
Table 2. Summary of ANOVA results
Dependent
variable Factors Covariates
CaP% by sex Half decades (P <
0.001)
None
Contrast for trend
(P < 0.001)
Sex (P < 0.001)
Half decadesa
Sex (P = NS)
Age at first
stone
CaOx vs. CaP (P <
0.001)
None
Sex (P = NS)
Duration of
stone
disease
Sex (P < 0.001)
CaOx vs. CaP
(P = NS)
Age at first stone (P < 0.001)
CaOx vs. CaPa
Sex (P = NS)
Stones per
patient
Sex (P = 0.03) Duration of stone disease
(P = NS)CaOx vs. CaP stones
(P = NS)
ESWL per
patient
CaOx vs. CaP (P <
0.001)
Number of stones per patient
(P < 0.001)
Duration of stone disease
(P < 0.001)
Sex (P = NS)
CaOx vs. CaPa
Sex (P = NS)
ESWL per
patient
CaP% (P < 0.0001) Number of stones per patient
(P < 0.0001)
Duration of stone disease
(P < 0.001)
Contrast for trend
(P < 0.001)
CaP%
continuous
variable
ESWL (1–5) (P <
0.001)
Number of stones (P = NS)
Duration of stone disease
(P = NS)Contrast for trend
(P < 0.001)
ESWL per
patient
Brushite vs. CaP(b)
(P < 0.001)
Number of stones per patient
(P < 0.001)
Duration of stone disease
(P = NS)Sex (P
= NS)
Brushite vs. CaP(b)a
Sex (P = NS)
ESWL per
patient
Brushite vs. CaP(b)
vs. CaOx (P <
0.001)
Number of stones per patient
(P < 0.001)
Duration of stone disease
(P = 0.009)
Abbreviations are: ESWL, extracorporeal shock wave lithotripsy; CaP%,
percent calcium phosphate in stones; CaOx, calcium oxalate; CaP, calcium
phosphate. P values for significance of factors and covariates are in parentheses.
The Table contains nine numbered analyses referred to in the text when needed
for clarity. NS, P > 0.05.
aIndicates the cross product for interactions between factors, or factors and
covariates.
men and women, respectively, P < 0.01 for both), and
had both higher SS CaP (1.5 vs. 2.2 and 1.5 vs. 1.8, CaOx
vs. CaP, men and women, respectively, P < 0.01 for both),
and higher urine pH (6.0 vs. 6.29 and 6.0 vs. 6.26, CaOx vs.
CaP, men and women, respectively, P < 0.01 for both). Put
another way, CaP SS increase correlated with increased
stone CaP%, as one would expect if both were being cor-
rectly measured.
The main correlates of CaP SS derived from step-wise
general linear modeling were calcium excretion, urine
volume, and urine pH for men (F = 7.4, 6.9, and 5.2,
respectively, all P < 0.001), and phosphorus excretion,
citrate excretion, and urine pH for women (F = 3.75, 2.9,
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Fig. 4. Urine stone risk factors with increasing stone CaP%. As expected, CaP supersaturation (SS) rose with stone CaP% (left upper panel, y-
and x-axis, respectively) among men (gray circles) and women (black circles; values are mean ± SEM). Urine pH rose progressively (upper middle
panel), which would increase CaP SS. Urine calcium excretion (upper right panel) rose to a plateau in men, but rose and fell in women. Urine
volumes were higher at high CaP% values in both sexes, although mean values for CaOx and CaP patients did not differ (lower left panel). Urine
phosphorus excretion was variable with no specific pattern (lower middle panel). Urine citrate excretion was lowest when CaP% was highest (lower
right panel), but SEM values were very wide and generally overlapping, and no significant trend could be proven.
and 2.7, respectively, all P < 0.01). Urine pH was the
common element for both sexes, and increased SS CaP
was an obvious physical explanation for the high CaP%
of stones. The increase of pH itself is not explained by
our present set of data.
Few measurements distinguish CaP(b)
from brushite stone formers
Urine calcium, oxalate, and phosphate differed for
male CaP(b) versus brushite patients, citrate excretion
for females. All three were higher for males with brushite
(335 vs. 265, 51 vs. 43, and 1160 vs. 1000, all mg/day, cal-
cium, oxalate, and phosphate, respectively, brushite vs.
CaP(b); P < 0.01, all three). Citrate excretion was low
for females with brushite (387 vs. 509, P = 0.045). Lack
of any measurement common to both sexes clouded in-
terpretation of these differences.
Number of ESWL procedures varies with stone
type but not sex, and rises with CaP%
ESWL use was more frequent among patients with CaP
than CaOx stones, adjusting for sex and stone type as
factors, and number of stones formed per patient and du-
ration of stone disease in years as covariates (Table 2;
analysis 5). Mean numbers of ESWL procedures per pa-
tient, adjusted for number of stones and duration of stone
disease were 0.64 versus 1.86 and 0.73 versus 1.82, CaOx
versus CaP, men and women, respectively. Adjusted least
square means for ESWL treatments rose smoothly with
CaP% after the 1% to 15% category, apart from a single
dip at 90% to 99% (Fig. 5, left panel). Post-hoc step-wise
contrast was highly significant (Table 2; analysis 6).
CaP% considered as a continuous variable, rose with
number of ESWL procedures per patient (Fig. 5, right
panel, and Table 2; analysis 7), adjusting for number of
stones per patient and duration of stone disease. Post-hoc
step-wise contrast was highly significant (Table 2; analysis
7). For this analysis, the few numbers of ESWL treatments
above five per patient were pooled into one category with
five ESWL per patient, and the whole group set as ‘5.’ All
in all, CaP% is strongly related to ESWL number, not to
number of stones or duration of stone disease.
Mean number of ESWL treatments per patient was
higher with brushite versus CaP(b), adjusted for sex,
number of stones per patient, and duration of stone dis-
ease (Table 2; analysis 8; 2.90 vs. 1.02 and 3.11 vs. 1.35,
brushite vs. CaP(b), ESWL/patient, males and females,
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Fig. 5. Relationship of extracorporeal shock
wave lithotripsy (ESWL) and CaP% in stones.
Number of ESWL procedures per patient (A)
rose smoothly with CaP% above 20%; the
trend by analysis of variance (ANOVA) with
post-hoc step-wise contrast was highly signif-
icant (P < 0.001). Average CaP% in stones,
considered as a continuous variable, rose with
number of ESWL procedures per patient (B).
ESWL numbers per patient of 5 and above
were truncated to 5 to avoid small cell size.
The trend was highly significant by post-hoc
testing. Values are mean ± SEM.
respectively, P < 0.001). ESWL per patient was higher
with brushite and CaP(b) versus CaOx (Table 2; analysis
9), adjusted for number of stones per patient and duration
of stone disease (2.96, 1.12, and 0.66 ESWL per patient,
brushite, CaP(b), and CaOx, respectively).
Treatment outcomes
Urine SS for CaOx and CaP, and urine calcium and
pH all changed in both sexes as inverse functions of their
pretreatment values (Fig. 6), as we have shown elsewhere
[11]. For both sexes, all four regressions were highly sig-
nificant (P < 0.001, all cases). The regressions did not
differ between CaOx (Fig. 6, solid lines) and CaP (Fig. 6,
dashed lines) patients except in the case of males, for
change in pH and SS CaP. CaP stone former SS CaP val-
ues lay above those for CaOx stone formers, but with the
same slopes, whereas the slope of urine pH change on ini-
tial urine pH was more shallow for CaP than CaOx stone
formers.
Despite the variable and modest differences in SS CaP
and pH changes in males, stone relapse did not differ
between the two groups (Fig. 7). In a Cox model with
pretreatment number of stones and numbers of ESWL
procedures, and time from first stone to treatment as co-
variates, only the number of pretreatment stones was sig-
nificant (P = 0.007), as we [6] have shown in the past.
Adjustment for al three variables did not alter the con-
clusion that treatment effects were not different.
DISCUSSION
Sex differences and CaP in stones over time
Although we are the first to contrast large groups of
CaP and CaOx stone forming patients, others have found
increased stone CaP over time in their studies of stones
[3, 12–14]. All studies to date agree about the time change
in CaP%, even though definitions of stone type and the
fractions of particular phases in stones labeled CaP(b) or
brushite vary among studies. Like us, others have found
that females predominate among CaP stone formers [15].
That stones containing any brushite are formed more by
men is new, as is the earlier stone onset age in CaP stone
formers. Unlike Leusmann [16], we did not find higher
stone rates in brushite stone formers. However, we did
find a higher number of stones in men, unexplained by
stone type or duration of stone disease. Finally, it should
be said by way of perspective that most studies have fo-
cused upon series of collected stones, whereas we pro-
ceeded via a large series of collected stone patients. The
correspondence of outcomes strongly supports the in-
crease in stone CaP, just as it incidentally supports the
validity of routine stone analyses.
ESWL and CaP stones
ESWL rate was higher for CaP than CaOx stone for-
mers, and highest of all for those with any stone contain-
ing brushite. ESWL per patient rose in a ‘dose response’
manner with eight grades of stone CaP%, and average
percent of CaP in stones rose with number of ESWL pro-
cedures over the range of 0 to ≥5 per patient. Neither
number of stones per patient nor duration of stone dis-
ease accounted for this linkage, whose power suggests a
strong causal relationship of a yet uncertain direction.
Cystine and brushite are the most difficult stones to
fragment by ESWL, with calcium oxalate monohydrate
stones a close third, followed by hydroxyapatite, stru-
vite, calcium oxalate dihydrate, and uric acid stones [17–
21]. Klee et al [4] showed a 65% success rate of ESWL
monotherapy for brushite stones (including fragments
less than 4 mm), with a mean of 1.5 ESWL sessions
per stone; only 11% of the patients became stone free.
Brushite stones are said by some to notably recur [4,
16, 22, 23]. We did not find increased numbers of stones
adjusted for stone disease duration. Medullary sponge
kidney and urinary tract malformations may be unusu-
ally frequent in brushite stone formers [14, 16]. These
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Fig. 6. Changes in urine measurements with treatment. Change in urine SS CaP, calcium excretion, pH, and SS CaOx are plotted against pre-
treatment values for female (top panels) and male (bottom panels) calcium oxalate (gray circles) and CaP (black circles) stone formers. Best-fit
regression lines for CaP patients (dashed lines) differ significantly from CaOx (solid lines) for male SS CaP and pH changes (see text). All individual
regressions are significant (P < 0.01).
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Fig. 7. Survival analysis of stone relapse during treatment. The fraction
of patients free of relapse falls similarly with time in CaP (lower line)
and CaOx stone formers. The two graphs do not differ. A 25% relapse
occurred at 6.8 and 8.4 years, CaP and CaOx, respectively.
factors could increase ESWL use. We did not observe
this association here.
Neither stone hardness nor recurrence explains our
findings, however. Though not harder to fragment than
CaOx stones, CaP(b) stones required more ESWL pro-
cedures. Our ESWL rates were corrected for numbers
of stones per patient and duration of stone disease. CaP
stones may be larger than CaOx stones, and less able to
pass [15, 24], so more ESWL is needed. CaP patients re-
quired surgery for stone removal more often than CaOx
stone formers before ESWL was available [25]. This is an
explanation we could not test here.
Shock waves injure blood vessels and tubules in the
treated kidney and transiently lower blood flow in both
kidneys [21]. Medullary collecting duct cell and vasa recta
injuries advance to include renal cortex veins and arter-
ies as shock number and/or discharge voltage increases
[26, 27, 28]. Scars can extend from the papillary tip to the
renal capsule [21, 29] and be associated with increased
blood pressure [30] and renal resistive index [31]. Col-
lecting duct cell injury could impair local acidification
and thereby foster CaP stone formation. This conjecture
should be evaluated in other research protocols.
CaP% and brushite versus CaP(b)
in relation to urine chemistry
Urine pH and CaP SS rose progressively with stone
CaP% in both sexes. High urine pH is usual in CaP stone
formers [1, 2, 15, 25, 32, 33]. We presume that SS CaP
is the driving force for CaP stones, and high pH a main
factor that raises it. Although brushite is the favored crys-
tal phase of CaP at pH below 6.5 and higher pH favors
CaP(b), we found no difference in mean urine pH or SS
CaP between brushite and CaP(b) stone formers. The
higher urine calcium, oxalate, and phosphate in men with
brushite in stones, and lower citrate in women are not im-
mediately interpretable. The findings that urine SS CaP
and pH vary proportionally with mean stone CaP% con-
firms and extends our past work showing that [1, 2] urine
SS correlates with stone compositions in two different
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populations, and that when SS and stone type diverge
there are compelling clinical reasons why [34].
Brushite is the initial urine CaP phase and transforms
to CaP(b) [35].We have found that the upper limit of
metastability for brushite, the level of SS at which crys-
tals begin to form spontaneously, is lower in stone for-
mers than in normal subjects [36, 37]. This may reflect
lack of inhibitors of crystallization, such as citrate, in the
urine [38]. Perhaps inhibitors that affect the conversion of
brushite to CaP(b) vary among our patients. These issues
are beyond the scope of this research. Also beyond the
present research is the cause of high urine pH. In small
groups of patients, we and others [25, 33] have found acid-
ification defects. We did not look for these in our present
patients.
Significance of abundant calcium phosphate
found in routine stone analyses
Calcium phosphate from routine stone analyses can
be highly informative, even though the sources are di-
verse and not necessarily attuned to research standards.
Such measurements in this work were sufficient to dis-
close time variations in stone CaP% like those reported
from reference laboratories. They showed us that women
had more stone CaP as CaP(b), whereas men had their
CaP as brushite. Patients with more than 50% CaP in even
one stone were younger at stone disease onset, but their
numbers of stones were not larger; men formed more
stones than women, whatever the CaP% or stone dura-
tion. The percent of CaP in stones and SS CaP progressed
in parallel, as one would expect from physical chemistry,
but that one is almost surprised to find in so coarsely
grained an experiment as we have conducted. For rea-
sons not yet known, ESWL procedures were more fre-
quent in CaP than CaOx stone formers and highest of all
in patients with brushite in stones. This is of high poten-
tial importance, and newly described here. Altogether,
the impression forces itself upon one’s mind that howso-
ever mundane the analysis and its sources, the CaP% of a
routine stone analysis carries a lot of information, much
of it of interest to clinicians and researchers.
The work is limited ultimately by the information con-
tent of the analyses themselves. What we can discern in
the way of relationships between CaP%, and brushite or
not in stones must be robust enough to overcome random
errors, from analytical vagaries and the fact that what is
analyzed as a stone may be a whole stone, or fragments
of one, and the latter may not reflect the CaP% of the en-
tire stone. The problem is in what we did not find. There
may be relationships between CaP% and other variables
that are obscured by random variations and might be dis-
cerned if our analyses were all performed in a crystal-
lographic laboratory. On the other hand, from a clinical
standpoint, the analyses we have here are what doctors
will have, and what we have found is pertinent to actual
clinical practice.
CONCLUSION
A number of issues call for additional research. Does
a high urine pH predict conversion from CaOx to CaP
stones? Are the ESWL procedures a cause or an effect
of CaP stones, especially of the brushite variety? Why do
CaP stone formers begin their disease at an earlier age?
Why do females have a higher urine pH than males? Is pH
the reason females have more CaP stones? Are potassium
citrate drugs that can raise pH a reason for increased CaP
stones? The present work cannot further resolve these
matters.
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